DelveInsight’s ‘Migraine Market Insights, Epidemiology, and Market Forecast—2032’ report delivers an in-depth understanding of the Migraine, historical and forecasted epidemiology as well as the market trends in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Migraine Overview
Migraine is a neurologic disorder that often causes a strong headache. The headache comes in episodes and sometimes also comes with nausea, vomiting, and sensitivity to light. Migraine is a leading cause of disability worldwide. Approximately 15% of Americans experience migraines. Most people who have migraines feel that people who do not have them often underestimate their condition. The exact cause of migraines is unknown, although they’re thought to be the result of temporary changes in the chemicals, nerves, and blood vessels in the brain. Migraines affect people’s quality of life and ability to participate in work, family, and social events. Migraines are a leading cause of disability and suffering worldwide.
Migraine Epidemiology Insights
-
The total Migraine prevalent population in the 7MM was 118,491,327 cases in 2021.
-
In 2021, the Migraine market size in the seven major markets was found to be USD 6,960.14 million in 2021, which is expected to grow by 2032.
Click here to learn more about the Migraine Market Landscape
The Report Covers the Migraine Epidemiology Segmented by:
-
Migraine prevalent cases
-
Migraine diagnosed cases
-
Migraine treatment cases
-
Migraine incident cases
-
Migraine cases based on age
Migraine Market Outlook
The Migraine market outlook of the report helps build a detailed comprehension of the historical, current, and forecasted Migraine market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology. This segment gives a thorough detail of the Migraine market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Migraine market in the 7MM is expected to change in the study period 2019-2032.
Key Companies Working in the Migraine Market
Lundbeck
Seattle BioPharmaceutical
Eli Lilly and Company
Amgen
Novartis
Teva Pharmaceuticals
Allergan
Biohaven Pharmaceuticals
Dr. Reddy’s Labs
AbbVie
Impel NeuroPharma
Zosano Pharma
Axsome Therapeutics
Aeon Biopharma Inc.
Ionis Pharmaceuticals, Inc.
Charleston Laboratories
And many others
Migraine Therapies Covered and Analyzed in the Report:
-
INP104
-
Eptinezumab
-
Metoclopramide
-
Ketorolac
-
Sumatriptan
-
Telcagepant
-
LY2951742
-
Intravenous Topiramate
-
Lacosamide
-
Rimegepant
-
Frovatriptan
-
Erenumab
-
Ibuprofen
-
Bupivacaine Hydrochloride
And many others
Learn more about the Key Companies and Emerging Therapies in the Migraine Market
Table of Contents
-
Key Insights
-
Migraine – Introduction
-
Executive Summary of Migraine –
-
Disease Background and Overview
-
Epidemiology and patient population
-
Migraine Emerging Therapies
-
Migraine Market Outlook
-
Market Access and Reimbursement of Therapies
-
Market Drivers
-
Market Barriers
-
Appendix
-
Report Methodology
-
DelveInsight Capabilities
-
Disclaimer
Learn about the detailed offerings of the report @ Migraine Market Outlook.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services